Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.
Frontier Medicines is a precision-medicine biotech using chemoproteomics, covalent chemistry, and machine learning to drug proteins long considered 'undruggable.' Its lead candidate, FMC-376, is a first-in-class dual ON/OFF inhibitor of KRAS G12C now in the Phase 1/2 PROSPER trial. Backed by $315M+ in venture funding and a major AbbVie partnership, the company is one of the most-watched names in next-generation targeted cancer therapy.
Arthur T. Sands, M.D., Ph.D., is the President and CEO of Nurix Therapeutics, a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines. A co-founder of Lexicon Pharmaceuticals in 1995, he spent 19 years transforming that company from a research startup into a drug-development enterprise generating over $450 million in revenue. At Nurix, he leads efforts to deploy a proprietary DEL-AI platform - combining DNA-encoded libraries with machine learning - to discover and develop small-molecule degraders and degrader-antibody conjugates for cancer and inflammatory diseases. The company's lead asset, bexobrutideg (a BTK degrader), entered pivotal Phase 2 development in 2025 with an 83% objective response rate in relapsed CLL patients.
Jorge F. DiMartino, M.D., Ph.D., is Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium, a San Diego-based biotech pioneering targeted protein degradation. A physician-scientist trained in genetics, immunology, and pediatric oncology across UC Berkeley, Cornell, UC San Diego, and Stanford, DiMartino has spent over two decades advancing cancer drugs from bench to bedside. His fingerprints are on three now-marketed therapies: vismodegib, venetoclax, and enasidenib - each a breakthrough in its own right. At Plexium, he oversees clinical programs targeting SMARCA2, IKZF2, CDK2, and CRAF using the company's DELTA Discovery platform, a novel approach to degrading proteins previously considered undruggable.
Chris Varma, Ph.D., is Co-Founder, Chairman, and CEO of Frontier Medicines, a clinical-stage biotech attacking cancer's 'undruggable' proteins using chemoproteomics, covalent chemistry, and machine learning. A serial biotech founder with 20+ years in life sciences, he previously co-founded Blueprint Medicines (acquired by Sanofi for $9B+ in 2025) and Warp Drive Bio (acquired by Revolution Medicines in 2018), and held investor roles at Third Rock Ventures, Flagship Pioneering, and MPM Capital. His career spans the FDA, Novartis, and three successful company builds - with Frontier Medicines now advancing FMC-376, a first-in-class dual KRAS G12C inhibitor, through Phase 1/2 clinical trials.